查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926882

Glucagon-Like Peptide-1促效劑市場（依產品、適應症、給藥途徑、通路及最終用戶分類）－2026-2032年全球預測

Glucagon Like Peptide-1 Agonists Market by Product, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Glucagon-Like Peptide-1促效劑市值將達到 134.1 億美元，到 2026 年將成長至 145.8 億美元，到 2032 年將達到 254.3 億美元，複合年成長率為 9.56%。

關鍵市場統計數據
基準年 2025 134.1億美元
預計年份：2026年 145.8億美元
預測年份 2032 254.3億美元
複合年成長率 (%) 9.56%

明確闡述GLP-1受體促效劑的臨床發展方向、給藥創新、支付方考量、對相關人員的策略意義

Glucagon-Like Peptide-1(GLP-1) 受體促效劑類藥物已迅速從糖尿病的小眾治療領域發展成為內分泌、肥胖和基層醫療等多個臨床和商業性領域的熱門療法。過去十年，胜肽工程、製劑和遞送技術的進步不斷突破療效的界限，同時也刺激了新的處方行為和支付方的興趣。因此，研究、生產、分銷和臨床護理等各個環節的相關人員正在重新評估關於患者治療路徑、治療連續性和療效評估的假設。

科學突破、監管調整、商業模式演變和供應鏈韌性如何共同重塑GLP-1治療領域的格局

在科學、監管和商業性因素的驅動下，GLP-1治療領域正經歷變革性的轉變，這正在改變競爭格局和病患的用藥途徑。長效製劑和口服胜肽技術的突破性進展減輕了給藥負擔，增強了處方醫師的信心，並使其得以在傳統專科診療範圍之外廣泛應用。同時，來自大規模臨床計畫的新安全性和有效性證據正在影響指南制定委員會和支付方的審查流程，促使人們制定更完善的報銷途徑和用藥管理方法。

評估2025年美國關稅變化對GLP-1供應鏈策略、供應商多元化和商業性韌性的營運影響

2025年美國新貿易關稅的實施對GLP-1的研發和商業化路徑產生了多方面的影響，在不改變其臨床價值提案的前提下，影響了籌資策略、生產計畫和成本結構。初期，由於關稅調整改變了相對進口成本，促使企業重新考慮供應商多元化，各組織面臨重新評估原料和成品採購合約的獎勵壓力。因此，一些製造商加快了在地化策略和替代採購方案的實施，以降低關稅波動和跨境物流延誤的風險。

透過深入的細分分析，將產品變體、臨床適應症、給藥途徑、通路和最終用戶環境與策略重點連結起來。

詳細的細分市場分析表明，產品層面的差異化是競爭定位的核心。Dulaglutide、Exenatide、Liraglutide和Semaglutide等分子展現出不同的臨床特徵、給藥間隔和製劑選擇，這些都會影響處方模式。這些差異與特定適應症的考量因素相互交織。針對肥胖症和第2型糖尿病的干涉措施有不同的支付方式、臨床終點和依從性預期，這些因素會影響商業策略和實證醫學證據的產生重點。因此，任何藥物的生命週期規劃都應整合其治療領域以及與每種適應症相關的獨特臨床和經濟價值提案。

區域採用模式和營運需求（美洲、歐洲、中東和非洲、亞太地區）指導區域打入市場策略和證據策略。

美洲、歐洲、中東和非洲以及亞太地區GLP-1療法的區域趨勢呈現出不同的應用促進因素和營運考量，因此需要採取量身定做的商業化和臨床應用策略。在美洲，法規結構、支付方結構以及與基層醫療的整合促進了GLP-1療法在特定臨床領域的快速應用，但處方行為仍受到報銷模式和專科醫療服務可近性的影響。因此，該地區的策略往往側重於支付方證據基礎、真實世界結果的收集以及與綜合醫療系統的合作，以證明GLP-1療法在不同患者群體中的價值。

競爭格局洞察突顯了科學差異化、策略夥伴關係和生產規模如何塑造領導企業的市場定位

GLP-1領域企業間的競爭反映了科學差異化、策略夥伴關係和規模經濟的綜合作用。領先的生物製藥公司正投資於新一代製劑、拓展適應症和給藥技術，而生物技術創新者則專注於口服胜肽類藥物遞送、新型輔料和器械整合等細分市場優勢。與契約製造、專科藥房和數位醫療服務提供者建立合作關係，正成為加速商業化和擴大患者支持的熱門途徑。

為確保競爭優勢，應優先採取實際的行動，整合證據產生、供應鏈多元化、通路最佳化和夥伴關係策略。

為了因應不斷發展的GLP-1市場，產業領導者應制定一項優先行動計劃，重點關注臨床差異化、供應鏈韌性、與支付方合作以及以患者為中心的服務模式。首先，企業應加快收集比較療效和真實世界依從性數據，以證明GLP-1在肥胖症和第2型糖尿病適應症中的價值，並透過產生符合支付方和指南決策標準的證據來支持更廣泛的市場准入。其次，透過多元化採購管道並加強與契約製造組織（CMO）的合作，可以確保關鍵臨床項目的持續供應，同時降低關稅和地緣政治風險。

為了支持研究結果和建議，採用了透明且可重複的調查方法，整合了臨床文獻、監管資訊來源、專家訪談和情境分析。

本分析整合了同行評審文獻、監管指導文件、公開臨床試驗註冊庫以及對臨床醫生、供應鏈高管和支付方代表的專家訪談，從而構建了一套透明且可複製的調查方法。資料點來自多個資訊來源，並經過三角驗證，應用於一個整合的工作流程，該流程能夠區分原始臨床證據、營運情報和商業性訊號。專家諮詢旨在深入了解處方行為、報銷決策的促進因素以及物流限制，並將這些發現與已記錄的政策變化和行業公告進行反覆檢驗。

一份簡潔的臨床、營運和政策見解綜合報告，重點闡述了GLP-1療法面臨的策略挑戰以及實現持續臨床和商業性影響的途徑。

總而言之，GLP-1療法的市場環境呈現出臨床創新、給藥方式不斷演進以及商業性模式轉變交匯融合的特點，這些因素共同為相關人員創造了機遇，同時也帶來了挑戰。製劑和給藥途徑的進步正在擴大潛在患者群體，但成功取決於臨床證據、支付方合作以及營運執行的協調一致。不斷變化的供應鏈和貿易政策凸顯了製定積極主動的籌資策略策略的必要性，而區域差異則要求採取個人化的商業化和循證方法，以實現持續的藥物可及性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Glucagon-Like Peptide-1促效劑市場產品

  • Dulaglutide
  • Exenatide
  • Liraglutide
  • Semaglutide

第9章Glucagon-Like Peptide-1促效劑市場依適應症分類

  • 肥胖
  • 2型糖尿病

第10章Glucagon-Like Peptide-1促效劑市場依給藥途徑分類

  • 口服
  • 皮下注射

第11章Glucagon-Like Peptide-1促效劑市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章Glucagon-Like Peptide-1促效劑市場（依最終用戶分類）

  • 診所
  • 居家醫療
  • 醫院

第13章 各地區Glucagon-Like Peptide-1促效劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Glucagon-Like Peptide-1促效劑市場（按組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國Glucagon-Like Peptide-1促效劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國Glucagon-Like Peptide-1促效劑市場

17. 中國Glucagon-Like Peptide-1促效劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Sun Pharmaceutical Industries
  • Viking Therapeutics
  • Zealand Pharma
Product Code: MRR-4F7A6D4FF354

The Glucagon Like Peptide-1 Agonists Market was valued at USD 13.41 billion in 2025 and is projected to grow to USD 14.58 billion in 2026, with a CAGR of 9.56%, reaching USD 25.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.41 billion
Estimated Year [2026] USD 14.58 billion
Forecast Year [2032] USD 25.43 billion
CAGR (%) 9.56%

A clear orientation to GLP-1 receptor agonists capturing their clinical evolution, delivery innovations, payer considerations, and strategic implications for stakeholders

The therapeutic class of glucagon like peptide-1 receptor agonists has evolved rapidly from a niche diabetes intervention to a broad clinical and commercial focus that intersects endocrinology, obesity care, and primary care practice. Over the past decade, advances in peptide engineering, formulation, and delivery have raised the therapeutic ceiling while catalyzing new prescribing behaviors and payer interest. As a result, stakeholders across research, manufacturing, distribution, and clinical care are reassessing assumptions about patient pathways, treatment persistence, and outcomes measurement.

In parallel, regulatory bodies have updated labeling considerations and real-world evidence requirements, prompting more rigorous post-approval safety monitoring and comparative effectiveness analyses. Consequently, product developers and commercialization teams have redirected resources toward lifecycle management, indication expansion, and adherence-supporting services. Taken together, these developments make an integrated view of clinical data, supply chain resilience, and stakeholder economics essential for any organization seeking to compete effectively within the GLP-1 ecosystem.

This introduction establishes the foundation for subsequent sections, which examine structural shifts, policy impacts, segmentation insights, regional dynamics, competitor behavior, recommended actions, and the methodological approach used to synthesize the available evidence and expert perspectives.

How scientific breakthroughs, regulatory recalibration, evolving commercial models, and supply chain resilience are together reshaping the GLP-1 therapeutic landscape

The GLP-1 therapeutic landscape is experiencing transformative shifts driven by scientific, regulatory, and commercial vectors that are altering competitive dynamics and patient access. Breakthroughs in long-acting formulations and oral peptide technologies have reduced administration burdens and expanded prescriber confidence, thereby enabling broader adoption beyond traditional specialist settings. At the same time, emerging safety and efficacy evidence from larger clinical programs has influenced guideline committees and payer review processes, prompting more nuanced reimbursement pathways and utilization management approaches.

Concurrently, commercial models are migrating from pure product sales toward integrated service offerings that support initiation, persistence, and remote monitoring. This transition reflects an understanding that real-world effectiveness depends on adherence and coordinated care, which many manufacturers and payers now seek to address through digital therapeutics partnerships and care management programs. Moreover, manufacturing and supply chain strategies are being revisited to secure active pharmaceutical ingredient sourcing, scale biologics production, and de-risk logistics in response to geopolitical and trade uncertainties. In sum, these shifts are creating a competitive environment where therapeutic differentiation is increasingly determined by the combination of clinical profile, delivery format, support services, and supply chain robustness.

Assessing the operational consequences of the 2025 United States tariff changes on GLP-1 supply chain strategies, supplier diversification, and commercial resilience

The imposition of new United States trade tariffs in 2025 has introduced layered effects across GLP-1 development and commercialization pathways, influencing sourcing strategies, production planning, and cost structures without altering clinical value propositions. Initially, organizations experienced immediate pressure to reassess procurement contracts for raw materials and finished goods, as tariff schedules changed relative import costs and created incentives to reexamine supplier diversity. Consequently, several manufacturers accelerated localization strategies or contingency sourcing plans to mitigate exposure to tariff volatility and cross-border logistical delays.

As a result, contractual negotiations with contract manufacturers and ingredient suppliers have intensified, with greater emphasis on long-term agreements and collaborative risk-sharing mechanisms. In addition, organizations have increased investments in forecasting and scenario planning to model tariff-driven operational permutations and to preserve margin stability. Over time, these responses are likely to produce a more diversified manufacturing footprint and heightened emphasis on vertical integration where commercially feasible. Importantly, while tariffs influence cost dynamics and supply chain decisions, clinical development timelines and regulatory approval criteria remain the primary determinants of product adoption, and stakeholders are advised to balance cost mitigation with uninterrupted clinical supply and quality assurance.

Insightful segmentation analysis connecting product variants, clinical indications, administration routes, distribution pathways, and end-user settings to strategic priorities

A granular segmentation view reveals that product-level differentiation is central to competitive positioning, with molecules such as Dulaglutide, Exenatide, Liraglutide, and Semaglutide demonstrating varied clinical profiles, dosing intervals, and formulation opportunities that influence prescribing patterns. These distinctions intersect with indication-specific considerations: interventions targeting obesity versus type 2 diabetes attract different payer pathways, clinical endpoints, and adherence expectations, which in turn shape commercial strategies and evidence generation priorities. Thus, lifecycle planning for any given agent should integrate its therapeutic niche and the unique clinical and economic value propositions associated with each indication.

Route of administration further stratifies the landscape, as oral delivery options compete for convenience and primary care uptake while subcutaneous presentations retain advantages in predictable exposure and established clinician familiarity. Distribution strategies must align with these administration choices; hospital pharmacy channels play a pivotal role in initiating complex regimens and inpatient continuity, online pharmacy models support convenience and patient retention, and retail pharmacy networks facilitate broad community access and point-of-care counseling. End-user contexts add another layer of nuance, with clinics often responsible for initiation and titration protocols, homecare settings enabling adherence continuity and convenience-based delivery models, and hospitals providing acute management and multidisciplinary coordination. Integrating these segmentation lenses allows commercial and clinical leaders to prioritize resources, design differentiated service models, and tailor evidence generation to the specific decision-makers across the treatment pathway.

Regional adoption patterns and operational imperatives across the Americas, Europe Middle East and Africa, and Asia-Pacific that guide localized go-to-market and evidence strategies

Regional dynamics for GLP-1 therapies display distinct adoption drivers and operational considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific, each requiring tailored approaches to commercialization and clinical engagement. In the Americas, regulatory frameworks, payer structures, and primary care integration have facilitated rapid uptake in certain clinical niches, yet prescribing remains sensitive to reimbursement models and specialty access. Therefore, strategies in this region often emphasize payer evidence dossiers, real-world outcomes collection, and collaboration with integrated health systems to demonstrate value in diverse patient populations.

Across Europe, the Middle East and Africa, heterogeneity in regulatory pathways and health technology assessment processes necessitates localized evidence strategies and flexible pricing mechanisms to navigate varied reimbursement environments. Stakeholders operating in these jurisdictions benefit from early HTA engagement and region-specific real-world evidence programs to address national decision criteria. In the Asia-Pacific region, rapid healthcare modernization, expanding primary care capacity, and increasing attention to metabolic disease management have created opportunities for scaled adoption, but success depends on culturally adapted patient support, supply chain scalability, and alignment with regional regulatory timelines. Recognizing these regional contrasts enables more precise go-to-market planning and allocation of resources where clinical impact and commercial traction are most attainable.

Competitive landscape insights highlighting how scientific differentiation, strategic partnerships, and manufacturing scale are shaping the leading players' positioning

Competitive dynamics among companies engaged in the GLP-1 space reflect a blend of scientific differentiation, strategic partnerships, and operational scale. Leading biopharma entities are investing in next-generation formulations, indication expansions, and delivery technologies, while biotech innovators focus on niche advantages such as oral peptide delivery, novel excipients, or device integration. Partnerships with contract manufacturers, specialty pharmacies, and digital health providers have become common levers to accelerate commercialization and extend patient support capabilities.

Consequently, organizational priorities vary by capability set: companies with extensive manufacturing capacity emphasize supply chain control and margin protection, those with strong clinical pipelines prioritize rapid evidence generation and regulatory sequencing, and commercially oriented players invest in channel orchestration and patient services. Across this spectrum, competitive differentiation increasingly depends on the ability to integrate clinical data with patient support systems, technology-enabled adherence solutions, and payer-aligned value propositions. Monitoring competitor moves in licensing, M&A, and distribution partnerships therefore remains essential for anticipating shifts in access and channel dynamics.

Practical prioritized actions for leaders to combine evidence generation, supply chain diversification, channel optimization, and partnership strategies to secure competitive advantage

Industry leaders should adopt a set of prioritized actions to navigate the evolving GLP-1 landscape, focusing on clinical differentiation, supply chain resilience, payer engagement, and patient-centric service models. First, companies must accelerate collection of comparative effectiveness and real-world adherence data that demonstrate value across both obesity and type 2 diabetes indications, aligning evidence generation with payer and guideline decision criteria to support broader access. Second, diversification of sourcing and increased collaboration with contract manufacturing organizations can mitigate tariff and geopolitical risk while preserving supply continuity for critical clinical programs.

Third, organizations should design channel strategies tailored to administration routes and end-user contexts, ensuring that oral delivery options are supported by primary care education and that subcutaneous therapies are paired with initiation and monitoring services. Fourth, investment in digital adherence tools and integrated care pathways will enhance persistence and outcomes, strengthening payer conversations and patient satisfaction. Finally, leaders should explore strategic partnerships and licensing arrangements that accelerate capability acquisition in areas such as oral peptide formulation, homecare delivery, and data analytics; such collaborations can compress time-to-value and spread development risk. Implementing these recommendations through cross-functional governance will enable faster, more coordinated responses to clinical, regulatory, and commercial challenges.

A transparent and reproducible research methodology integrating clinical literature, regulatory sources, expert interviews, and scenario analysis to underpin the study's findings and recommendations

This analysis synthesizes peer-reviewed literature, regulatory guidance documents, publicly available clinical trial registries, and expert interviews with clinicians, supply chain executives, and payer representatives to produce a transparent and reproducible methodology. Data points were triangulated across sources and subjected to a synthesis workflow that distinguishes primary clinical evidence from operational intelligence and commercial signals. Expert consultations were structured to capture perspectives on prescribing behavior, reimbursement decision drivers, and logistical constraints, and these insights were iteratively validated against documented policy changes and observed industry announcements.

Analytical frameworks included segmentation mapping, scenario analysis for tariff and supply chain responses, and comparative assessments of delivery formats and distribution channels. Quality assurance steps encompassed source cross-verification, consistency checks across datasets, and follow-up interviews to resolve discrepancies. Where applicable, real-world evidence interpretations prioritized outcomes that align with payer and clinician decision-making, such as adherence patterns and treatment persistence, rather than proprietary commercial metrics. Collectively, this methodological approach balances rigor with practical relevance to support actionable conclusions for stakeholders across the therapeutic, commercial, and regulatory spectrum.

A concise synthesis of clinical, operational, and policy insights that clarifies strategic imperatives and the pathways to sustained clinical and commercial impact in GLP-1 therapies

In synthesis, the GLP-1 therapeutic landscape is defined by converging clinical innovation, evolving delivery modalities, and shifting commercial paradigms that together present both opportunity and complexity for stakeholders. Advances in formulations and administration routes are broadening the potential patient base, yet success depends on the alignment of clinical evidence, payer engagement, and operational execution. Supply chain and trade policy developments underscore the need for proactive sourcing strategies, while regional heterogeneity requires tailored commercialization and evidence approaches to achieve durable access.

Therefore, organizations that invest in differentiated clinical data, robust supply chain planning, and patient-centric service models will be best positioned to translate therapeutic promise into sustained clinical impact and commercial viability. Cross-sector collaboration-spanning manufacturers, payers, care providers, and technology partners-will accelerate the formation of integrated care pathways that maximize the real-world benefits of GLP-1 therapies. Ultimately, strategic clarity, operational preparedness, and a relentless focus on patient outcomes will determine which stakeholders lead in this rapidly maturing therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glucagon Like Peptide-1 Agonists Market, by Product

  • 8.1. Dulaglutide
  • 8.2. Exenatide
  • 8.3. Liraglutide
  • 8.4. Semaglutide

9. Glucagon Like Peptide-1 Agonists Market, by Indication

  • 9.1. Obesity
  • 9.2. Type 2 Diabetes

10. Glucagon Like Peptide-1 Agonists Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Subcutaneous

11. Glucagon Like Peptide-1 Agonists Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Glucagon Like Peptide-1 Agonists Market, by End User

  • 12.1. Clinic
  • 12.2. Homecare
  • 12.3. Hospital

13. Glucagon Like Peptide-1 Agonists Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glucagon Like Peptide-1 Agonists Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glucagon Like Peptide-1 Agonists Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Glucagon Like Peptide-1 Agonists Market

17. China Glucagon Like Peptide-1 Agonists Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen
  • 18.6. AstraZeneca
  • 18.7. Boehringer Ingelheim
  • 18.8. Dr. Reddy's Laboratories
  • 18.9. Eli Lilly and Company
  • 18.10. Novo Nordisk
  • 18.11. Pfizer
  • 18.12. Roche
  • 18.13. Sanofi
  • 18.14. Sun Pharmaceutical Industries
  • 18.15. Viking Therapeutics
  • 18.16. Zealand Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)